Both in Pharmaceuticals
Xenetic Biosciences vs Apimeds Pharmaceuticals US
Over the past year XBIO returned −33.3% and APUS returned −88.0%; their daily moves had a correlation of 0.06.
XBIO −33.3% APUS −88.0%Growth of $1, one year, split-adjusted
| Metric | XBIO | APUS |
|---|---|---|
| Price | $2.08 | $2.97 |
| Market cap | $4.9M | $4.5M |
| Today | +0.97% | +2.77% |
| 1 month | −5.5% | −35.3% |
| 6 months | −32.7% | −90.1% |
| Year to date | −4.1% | −81.9% |
| 1 year | −37.7% | — |
| Revenue growth (YoY) | +12.0% | — |
| Gross margin | 100.0% | — |
| Net margin | −140.7% | — |
| P/E (TTM) | — | — |
| Price / sales | 3.3× | — |
| Net cash | $6.5M | -$8.6M |
| Dividend yield | — | — |
| Volatility (60d) | 158.7% | 264.0% |
| Short % of float | 0.5% | 0.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).